Jefferies on Structure Therapeutics (GPCR): 'We think the topline data is compelling and believe it reinforces a Ph3 ready profile with best-in-class weight loss'
Tweet Send to a Friend
Jefferies analyst Roger Song reiterated a Buy rating and $79.00 price target on Structure Therapeutics (NASDAQ: GPCR).The analyst comments "GPCR ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
